
Brenmiller Energy Ltd. announces a partnership with Baran Energy to boost bGen™ ZERO Thermal Energy Storage. Read the February 2025 Form 6-K for key insights and developments.

Brenmiller Energy Ltd. announces a partnership with Baran Energy to boost bGen™ ZERO Thermal Energy Storage. Read the February 2025 Form 6-K for key insights and developments.

Explore Chijet Motor Company, Inc.'s SEC Form 6-K filing for February 2025, detailing recent developments and leadership accountability.

Explore VersaBank's Form 6-K for February 2025, detailing financial results, a conference call on March 5, and key compliance info. Stay updated with investor insights!

Discover SciSparc Ltd.'s significant legal victory in its February 2025 Form 6-K report, detailing a favorable settlement that enhances financial standing and operational commitments.

On Feb 13, 2025, Vodafone Group Plc reported significant share purchases by directors via a Dividend Reinvestment Plan, showcasing their commitment and confidence in the company's future.

Explore Bioceres Crop Solutions Corp.'s SEC Form 6-K for February 2025, featuring Q2 financial results and operational insights signed by CEO Federico Trucco.

Explore Linkage Global Inc's January 2025 Form 6-K report, covering upcoming extraordinary meetings, notices, and proxy statements for shareholders.

Discover Arbe Robotics Ltd.'s significant $27M underwritten offering, key details, and implications for corporate growth in this essential Form 6-K report.

Discover key insights from Clearmind Medicine Inc.'s January 2025 SEC Form 6-K, including a new patent for binge behavior treatment, enhancing its market position and compliance.

Explore LOBO EV Technologies Ltd.'s significant auditor change and financial insights in their December 2024 Form 6-K report. Key updates on management practices and audit integrity.

Discover key insights from AIX Inc.'s SEC Form 6-K, detailing a $140M share exchange with BGM Group, boosting AIX's influence in the healthcare tech sector.

Explore PolyPid Ltd.'s Form 6-K detailing a $14.5M private placement to support SHIELD II Phase 3 trials, with potential additional $27M from warrants. Key financial insights included.